KalVista Pharmaceuticals, Inc. Common Stock
KALVKalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other medical conditions. Founded in 2009 and based in the United States, the company aims to advance targeted therapies to improve patient outcomes through innovative drug development and clinical programs.
Company News
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from app...
Monteverde & Associates PC is investigating four merger transactions: Talkspace's sale to Universal Health Services at $5.25/share, Lisata Therapeutics' sale to Kuva Labs at $4.00/share plus contingent value rights, National Storage Affiliates Trust's sale to Public Storage at 0.14 shares per unit, and KalVista Pharmaceuticals' sale to Chiesi Gro...
U.S. stock futures advanced on Friday as investors awaited the December jobs report and the Supreme Court's ruling on Trump's tariffs. Major indices showed modest gains with SPY and QQQ trading higher in premarket. Key movers included General Motors facing EV investment losses, Tilray surging on earnings beats, Offerpad jumping on Trump's housing...
KalVista Pharmaceuticals launched EKTERLY, its first oral treatment for hereditary angioedema, generating $1.4 million in Q1 FY2026 revenue. The launch was accompanied by increased commercialization expenses and a widened net loss, reflecting the company's transition to commercial operations.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
